Sector News

Generics set to undercut blockbusters from Merck, Novartis and BMS

January 17, 2017
Life sciences

Several blockbusters are set to take a nosedive this year as patent losses hit Novartis, Merck & Co., Bristol-Myers Squibb and other top pharma companies.

Dickson Data has compiled a list of major drugs losing their IP protection this year, and standing at the top is Novartis’ Sandostatin LAR with $1.6 billion in annual sales. Used to treat acromegaly and severe diarrhea and flushing associated with carcinoid syndrome, the drug will quickly face generic erosion from a slew of companies, including Teva, Sun Pharma, Sagent Pharmaceuticals and Wockhardt.

Behind Sandostatin LAR is Merck’s antibiotic Cubicin, a key prize in the New Jersey pharma giant’s $9.5 billion purchase of Cubist Pharmaceuticals back in 2014. The drug currently tallies $1.17 billion in sales, according to Dickson, and is set to face cheaper rivals from Hospira, Teva and Crane Pharma, FDA records show.

Merck faces another blockbuster loss, too: Its cholesterol med Vytorin, with $1.12 billion in sales, comes in fourth place, according to Dickson. Bristol-Myers’ HIV drug Reyataz stands in third place with $1.14 billion.

Branded drugs tend to lose 90% of their sales after multiple generics make it to market, according to the firm. The copycats are typically 80 to 85% cheaper than the branded originals.

Although not a blockbuster like others on the list, Eli Lilly’s ADHD med Strattera rounds out the top five drugs facing a patent expiration, Dickson found, with annual sales just shy of $700 million. Zydus, Aurobindo, Sun Pharma and Mylan are among the companies seeking to grab a piece of that drug’s annual haul.

Merck’s antibiotic Invanz and antifungal med Cancidas are also set to lose patent protection for the New Jersey pharma giant; all told, the drugmaker has four meds totaling $3.8 billion in sales—10% of its total haul—susceptible to generics this year.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).